The Effect of Beta-glucan in Non-Small Cell Lung Cancer

Description

The purpose of this study is to determine how beta-glucan affects the immune system in subjects with non-small cell lung cancer.

Conditions

Non Small Cell Lung Cancer

Talk to us

Study Overview

On this page

Study Details

Study overview

The purpose of this study is to determine how beta-glucan affects the immune system in subjects with non-small cell lung cancer.

Beta-glucan's Immuno-modulatory Effect on Non-Small Cell Lung Cancer

The Effect of Beta-glucan in Non-Small Cell Lung Cancer

Condition
Non Small Cell Lung Cancer
Intervention / Treatment

-

Contacts and Locations

Louisville

James Graham Brown Cancer Center, Louisville, Kentucky, United States, 40202

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * suspected or definitive diagnosis of non-small cell lung cancer (NSCLC)
  • * treatment naive or no treatment within 6 months prior to enrollment
  • * able to swallow pills
  • * Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 3
  • * absolute neutrophil count (ANC) at least 1500/microl
  • * able to understand and willing to sign a written informed consent document
  • * history of hypersensitivity reactions attributed to beta-glucan
  • * currently receiving continuous corticosteroids or other ongoing immunosuppressive therapy
  • * presence of an uncontrolled intercurrent illness including but not limited to: ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements

Ages Eligible for Study

18 Years to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

University of Louisville,

Goetz H Kloecker, MD, PRINCIPAL_INVESTIGATOR, James Graham Brown Cancer Center

Study Record Dates

2029-03